这些投资将进一步深化阿斯利康在华研发布局，包括位于北京和上海的全球战略研发中心，这些中心与 500多家临床医院合作，并在过去三年中主导了大量全球临床试验。同时，公司将升级其位于无锡、泰 州、青岛和北京的生产基地，并适时宣布新建生产基地的计划。现有基地正在为中国及全球70多个市场 的患者提供高质量创新药品。通过这些投资，阿斯利康在中国的员工规模将超过2万人，并在整个医疗 健康生态系统中创造数千个新增岗位。 1月29日，阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局。 ...

关关关关关注注注注注投投投投投资资资资资界界界界界视视视视视频频频频频号号号号号 做做做做做创创创创创投投投投投圈圈圈圈圈最最最最最靓靓靓靓靓的的的的的仔仔仔仔仔 ...

Core Viewpoint - The company has engaged in investments related to the medical sector through an industrial fund, which aligns with its strategic layout around its main business and does not represent a new business direction [1] Group 1 - The company responded to an investor inquiry regarding its involvement with a brain engineering company, confirming participation in medical-related investments [1] - The investment was made in March 2024 and has been disclosed in accordance with regulatory requirements [1] - The company emphasized that these investments are part of its strategic focus and do not indicate a shift in its core business direction [1]

Core Viewpoint - Precision Medicine is set to debut on the Hong Kong Stock Exchange, aiming to raise approximately HKD 1.199 billion through the issuance of 27.7222 million shares at a price of HKD 43.24 per share, with trading expected to commence on January 8, 2026 [2][10]. Financial Performance - For the first half of 2025, Precision Medicine reported revenue of RMB 149 million and a gross profit of RMB 93.85 million [2][10]. Investment Background - Chengdu Mingsheng Investment Co., Ltd. invested RMB 5 million during the angel round, which has appreciated to RMB 675 million, yielding a remarkable return of 135 times over eight years [2][10]. - The company was founded in May 2017 and received its first investment four months later [3][10]. Shareholding Structure - As of the IPO, Chengdu Mingsheng holds 17.50464 million shares, representing 4.86% of the total shares, making it the fourth-largest shareholder [7][15]. - The major shareholders include Dr. Wang with 29.05% and Dr. Gao with 14.35% of the shares [15]. Future Prospects - The shares held by Chengdu Mingsheng are subject to a 12-month lock-up period post-IPO, with a market value of approximately HKD 757 million, equivalent to RMB 680 million [15].

Core Viewpoint - Pizhou Pharmaceutical has made a strategic investment in the healthcare sector by becoming a limited partner in the newly established CICC Medical Fund, contributing 200 million RMB, which represents 20% of the fund's target size of 1 billion RMB [1][2][3] Group 1: Investment Details - The CICC Medical Fund was established on October 14, with a target fundraising size of 1 billion RMB, and Pizhou Pharmaceutical's subsidiary, Zhangzhou Pizhou Investment Management Co., Ltd., is a limited partner contributing 200 million RMB [1][2] - The fund's primary investment focus includes traditional Chinese medicine, biomedicine, medical devices, healthcare services, and beauty and wellness industries, aligning with Pizhou's strategic interests [2][3] Group 2: Strategic Implications - Pizhou Pharmaceutical views this investment as a forward-looking strategy to enhance its core competitiveness while ensuring stable development of its main business [3] - The collaboration with CICC Capital is expected to leverage their extensive fund management experience and resources to integrate industry and capital effectively, supporting the long-term development of Pizhou and the healthcare industry in Zhangzhou [3] Group 3: Previous Investments - This is not Pizhou's first foray into the limited partner space; earlier in 2023, the company invested in two other funds, each with a similar contribution of 200 million RMB, focusing on the healthcare supply chain and biomedicine [4][5] - The previous investments are aimed at diversifying risks and linking innovative resources, which may provide future material supply guarantees for Pizhou's core products [5]

（股 份 代 號：3347） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 自願性公告 關於全資子公司購買日本MICRON部分股權 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） MICRON截 至2025年5月31日總資產78,094.76萬 日 元，淨 資 產-45,175.17萬 日 元；2025年1–5月主營業務收入93,959.78萬 日 元，淨 利 潤-6,704.74萬 日 元。 （以 上 數 據 未 經 審 計）。 一、股份購買概述 – 2 – 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 ...

关关关关关注注注注注投投投投投资资资资资界界界界界视视视视视频频频频频号号号号号 做做做做做创创创创创投投投投投圈圈圈圈圈最最最最最靓靓靓靓靓的的的的的仔仔仔仔仔 ...

ZERO IPO 清 科 创 业 2025 投资界百人 =0 CHINA INVESTORS 100 FORUM 2025 2025/02/28 中国·三亚 ( 部分出席嘉宾,按姓名音序排序 ) 陈涛 曹永刚 陈石 弘毅投资 峰瑞资本 北京科技创新投资管理有限公司 总裁 投资合伙人 常务副总经理 陈十游 优山投资 董事长 费飞 上海国投孚腾资本 总经理、管理合伙人 费建汇 元禾原点 管理合伙人 位于 蓝驰创投 投资合伙人 甘剑平 漢策资本 创始合伙人 顺康灾 钟鼎资本 合伙人 郝毓盛 纳斯达克交易所 中国区首席代表 黄升轩 北京泰康投资 CEO 傅哲院 啟赋资本 董事长、创始合伙人 高昂 前海母基金主管合伙人 天使投资基金总经理 官蒲玲 唐兴资本 创始人兼董事长 रू सर k控基金 CEO 黄高 壹叁資本 高级合伙人 李薇 华映资本 创始管理合伙人 广平平 启明创投 创始主管合伙人 李浩 中科创星 创始合伙人 李文隧 ker website in the sering to the sering to the sering to the sering to the sering the sering of ...